Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis

Posted on September 4, 2019 by Gastroenterology Journal

Interleukin 23 (IL23) contributes to pathogenesis of ulcerative colitis (UC). We investigated the effects of mirikizumab, a monoclonal antibody against the p19 subunit of IL23, in a phase 2 study of patients with UC.

This entry was posted in News. Bookmark the permalink.